JOSH'S STORY
In February of 2021, Josh’s parents noticed he was getting very pale. What was originally thought to...
Read Morea:1:{i:0;s:900:Medulloblastoma (MB) is a highly aggressive embryonic tumour of the cerebellum and the most common malignant brain tumour of childhood (1). Despite a cure rate of approximately 70-75% among children aged ?3 years, MB survivors continue to pay a high price, in terms of long-term adverse sequelae, for cure (2). A major drawback of the current therapy is that it fails to recognise the heterogeneity of MB patients. Detection and categorisation of this heterogeneity is of fundamental importance because a multitude of studies have shown that intrinsic differences in the molecular profiles of MBs result in substantial differences in disease manifestation and clinical outcome. Therefore, to improve cure rates among patients with molecularly aggressive MB and reduce treatment-related morbidities, a therapeutic strategy in which treatment is tailored to match these distinctions is urgently needed.;}
Grant Award – Kidscan Student Placement (2016 – 2017)
Funding Award – £2000.00
Funding Awarded to – Dr Gianpiero Di Leva
Research Location – University of Salford
Lead Researcher – Dr Gianpiero Di Leva
In February of 2021, Josh’s parents noticed he was getting very pale. What was originally thought to...
Read MoreWhat a whopper of a night - Friday 20th May, our ambassador Isla's mum Jill and family hosted...
Read MoreWe want to say a huge thank you to Lee Mossop, former Captain of RFL Salford Red...
Read More